Monte Rosa Therapeutics
CompanyUnited States
Monte Rosa Therapeutics develops one asset, in phase 1 (MRT-8102 in cardiovascular risk in obesity). Mostly small molecule acting on NLRP3 inflammasome, inflammation and NEK7; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Molecular glue degrader of NEK7 inhibiting NLRP3 inflammasome activation
Phase 1, Small molecule, NLRP3 inflammasome, Inflammation, cardiovascular risk in obesity, heart inflammation
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Similar companies6